J Biol Chem, Vol. 275, Issue 11, 8007-8015, March 17, 2000
Molecular Cloning of Mouse Ganglioside Sialidase and Its
Increased Expression in Neuro2a Cell Differentiation*
Takafumi
Hasegawa
§,
Kazunori
Yamaguchi
,
Tadashi
Wada
,
Atsushi
Takeda§,
Yasuto
Itoyama§, and
Taeko
Miyagi
¶
From the
Division of Biochemistry, Research
Institute, Miyagi Prefectural Cancer Center, 47-1 Nodayama,
Medeshima-shiode, Natori, Miyagi 981-1293 and the
§ Department of Neurology, Tohoku University School of
Medicine, Sendai, Miyagi 980-8574, Japan
 |
ABSTRACT |
Ganglioside sialidases have been implicated in
neuronal differentiation processes, including neurite outgrowth. To
understand further the roles and regulation mechanisms of the sialidase
in neuronal systems, we have cloned mouse ganglioside sialidase
cDNA and observed its expression in Neuro2a cell differentiation. A 3339-base pair cDNA, cloned based on the sequence information of
previously cloned enzymes, encodes 418 amino acids containing three Asp
boxes characteristic of sialidases. Northern blot analysis revealed a
3.4-kilobase transcript expressed highly in heart but also in several
other tissues including brain. In situ hybridization of
mouse brain demonstrated the mRNA to be present in the cerebral cortex, as well as in the granule cell layer, Purkinje cells, and deep
cerebellar nucleus of the cerebellum. Transient expression of the
cDNA in COS-1 cells resulted in over 300-fold increase in sialidase
activity toward gangliosides compared with the control level, with a
preference for ganglioside substrate. During
5-bromodeoxyuridine-induced Neuro2a cell differentiation, the
expression of the sialidase was increased as assessed by activity
assays and quantitative reverse transcription-polymerase chain reaction
analyses. Stable transfection of the sialidase in Neuro2a cells
resulted in accelerated neurite arborization following
5-bromodeoxyuridine treatment, indicating the direct participation of
this ganglioside sialidase in neuronal cell differentiation.
 |
INTRODUCTION |
In recent years, great interest has focused on the elucidation of
the biological function of glycosphingolipids, in particular gangliosides, which are characteristic constituents at the surface of
mammalian cells and abundant in neuronal membranes (1, 2). In the
nervous system, gangliosides have been observed to undergo metabolic
alterations during development and have been implicated in various
biological phenomena, including neuritogenesis (3, 4), synaptic
function (5), neuronal death (6), neural repair (7), cell-cell
recognition, and cell adhesion (8). Ganglioside accretion is largest
during dendritic arborization and synaptogenesis and is accompanied by
marked changes in the ganglioside composition, which then persist
during adult life (9, 10). Neuroblastoma cell lines can be triggered to
undergo neuronal differentiation with a marked alteration of
ganglioside patterns by several pharmacological agents (11-13). On the
other hand, a number of exogenous gangliosides are known to cause
neuritogenesis, including ganglioside GM1 (14), enhances the effects of
neurotrophic factors, such as nerve growth factor (15, 16), in several cell lines. Tsuji et al. (17) reported that very low amounts of exogenous GQ1b specifically stimulated neurite outgrowth in a human
neuroblastoma cell line, GOTO cells. Although the general mechanism by
which gangliosides promote neuritogenesis has not been elucidated,
their desialylation by endogenous as well as exogenous sialidases has
been suggested as a critical event for neuronal differentiation
(18-21), myelination (22), synaptogenesis, and synaptic function (23).
A potent ganglioside sialidase activity, in fact, is located in the
neuronal membranes (24), with a relative enrichment in the synaptosomal
fraction as compared with the neuronal perikarya (23, 25). In this
context, it is necessary to clarify the expression mechanisms of
endogenous sialidase responsible for ganglioside degradation in the
nervous system. In the present study, we obtained new insights into the
role of the ganglioside sialidase during neuronal differentiation by
studies with a newly cloned cDNA.
Mammalian sialidases, catalyzing the first step in glycoconjugate
degradation, have been classified based on their subcellular distribution into at least four types: cytosolic, lysosomal matrix, lysosomal membrane, and plasma membrane (26-28). They differ from each
other not only in subcellular location but also catalytic and
immunological properties. Membrane-associated sialidases hydrolyze gangliosides preferentially, and those in plasma membrane are distinct
from lysosomal membrane sialidase in acting specifically on
gangliosides residing in the same membrane (28, 29).We previously
cloned a cytosolic sialidase from rat skeletal muscle (30), and
recently membrane ganglioside sialidases of bovine (31) and human (32)
brains. Lysosomal sialidases of human (33-35) and mouse (36-38) were
also cloned by another three groups. We have now isolated a cDNA
encoding mouse ganglioside sialidase capitalizing on the high degree of
conservation in the primary structures of bovine plasma membrane (31),
rat cytosolic (30), and human lysosomal (33-35) sialidases. The
spatial and temporal expression of the sialidase mRNA was
investigated in adult mouse brain and during differentiation of Neuro2a
cells induced by 5-bromodeoxyuridine (BrdUrd).1 The results
revealed the ganglioside sialidase to be widely expressed in the
central nervous system and to play a positive regulatory role in
differentiation of neuronal cells.
 |
EXPERIMENTAL PROCEDURES |
cDNA Cloning of a Mouse Ganglioside Sialidase--
Possible
mouse ganglioside sialidase cDNA fragments were first amplified by
PCR using oligonucleotide primers, based on the amino acid sequences of
previously cloned sialidases. One pair of the primers, 1S
(5'-GGACACCGGACCATGAACCCCTGTCCT-3') (sense) and 2A
(5'-CCTGGCCCCACAGCAAAAGTGGCCCA-3') (antisense), and degenerate primers
3S (5'-AC(C/T)TT(C/T)CT(G/C)GCCTT(C/T)GC(A/T)GAG-3') and 4A (5'
CTG(A/G)AT(A/G) CCAI I(A/G)CC(C/T)GG(G/T)CCIII(A/G)GCAAA-3') were
designed from sequences in regions in which the amino acids of
the bovine membrane sialidase are identical to those of rat cytosolic
and of human lysosomal sialidases, respectively. The first strand
cDNAs were synthesized from poly(A)+ RNA from BALB/c
mouse brain, prepared by the acid guanidium-phenol-chloroform extraction procedure (39), followed by oligo(dT) column chromatography, using random primers and murine leukemia virus reverse transcriptase (Superscript RNase H
, Life Technologies, Inc.). The
cDNA was then used as a template for PCR under the following
conditions: initial denaturation at 95 °C for 5 min followed by 40 cycles of denaturation at 94 °C for 30 s, annealing at 55 °C
for 1 min, and extension at 72 °C for 2 min, with final elongation
at 72 °C for 10 min. Appropriate PCR products were gel purified and
blunt end-ligated to the SmaI site of a Bluescript vector.
At this step, three positive fragments (MBI, MBIIA, and MBIIB) were obtained.
To obtain a complete cDNA, the 3' and 5' ends of the mouse membrane
sialidase cDNA were extended according to the rapid amplification of cDNA ends (RACE) methods described by Frohman et al.
(40) with slight modifications. The primer 5A
(5'-ATCAGCCCTCGTCTGAGCACCA-3'), derived from the 5' end sequence
obtained from the degenerate PCR product MBIIA, was used in the reverse
transcription of the 5' end of the mRNA from mouse brain
poly(A)+ RNA. After reverse transcription, the RNA was
degraded by incubation for 15 min at 37 °C with 2 units of RNase H. The purified cDNA was polyadenylated at its 3' end by incubation
with 10 units of terminal deoxynucleotidyl transferase in the presence
of 6 mM ATP at 37 °C for 10 min. The mixture was then
heated to 65 °C to denature the enzyme, and the polyadenylated
single-strand cDNA (one-tenth of the aliquot of the cDNA pool
synthesized above) was applied directly in the first PCR amplification.
The poly(A) tail generated was used to initially amplify the cDNA
with the (dT)17 adaptor primer
(5'-GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT-3'), followed by further
amplification with the adaptor primer (5'-GACTCGAGTCGACATCG-3') and the
specific primers 6A (5'-AGGCAGCATCCTCATCTCTGAC-3') and 7A
(5'-TCATCTCTGACTGAGGTCCGCT-3'), deduced from the MBIIA fragment. In the first amplification, the cDNA was amplified using 37.5 pmol
of (dT)17 adaptor, 12.5 pmol of adaptor, and 25 pmol of 6A primer, using the following conditions: 95 °C for 5 min, 3 cycles of
94 °C for 30 s, 50 °C for 1 min, and 72 °C for 2 min
followed by 37 cycles of 94 °C for 30 s, 55 °C for 1 min,
and 72 °C for 1 min with final elongation at 72 °C for 10 min. A
2-µl aliquot of the PCR product was reamplified using 25 pmol of each
of the nested primers, adaptor, and 7A primer, under the same
conditions except for an annealing temperature of 55 °C.
For derivation of the 3' end, a (dT)17 adaptor, an adaptor,
and a set of oligonucleotides, 8S (5'-TTGACCGAGGAGGTCATTGG-3') and 9S
(5'-TCATTGGCTCAGAGGTGAAG-3') primers specific to the 3' end sequence of
the MBIIA fragment, were used as primers. First strand cDNA was
synthesized by reverse transcription of mouse brain
poly(A)+ RNA (1 µg) using the (dT)17 adaptor
primer. The single-stranded cDNA generated by reverse transcription
was purified from primers using a NICK column (Amersham Pharmacia
Biotech). The cDNA (one-tenth of the aliquot synthesized above) as
template, adaptor (12.5 pmol), and primer 8S (25 pmol) were used for
amplification as described above. A 2-µl sample of the product was
reamplified in 50 µl with adaptor primer (25 pmol) and a nested
specific primer (9S, 25 pmol).
cDNA Cloning of a Mouse Cytosolic Sialidase--
Mouse
cytosolic sialidase was cloned based on the primary structure of rat
cytosolic sialidase by RT-PCR and RACE methods in a manner similar to
that described above. Degenerate primers (sense,
5'-GAAGTCTATGCTTAC(A/C)GIA(T/C)CC-3'; antisense,
5'-AGCTTCCGGTAGGCATAAGC-3') were used in combination with template
cDNA reverse-transcribed from mouse skeletal muscle
poly(A)+ RNA. A 513-bp PCR fragment was obtained, and its
5' and 3' sequences were extended by the RACE methods using specific
primers derived from the fragment sequence: for 5'-RACE, mcSD1A
(5'-TGCTGGCTCGCTTTTCCGCAAA-3'), mcSD2A (AAAGGCCAGCAGGGTCTTCTGCTT-3'),
and mcSD3A (5'-TGCTTCTTCAGGTAGAGCAGAGCA-3'); for 3'-RACE, mcSD4S
(5'-GTCTGCAGCTGC GGAACCCAGCT-3') and mcSD5S (5'-AGCTGGGAGCCTGCTGGTACCT-3').
DNA Sequence Analysis--
The appropriate PCR products in
Bluescript were sequenced with a Model 4200L-2 DNA autosequencer
(LI-COR) using a Thermo Sequenase Cycle Sequencing Kit (Amersham
Pharmacia Biotech) with fluorescence-labeled M13 forward and reverse
primers. Nucleotide and amino acid sequences thus obtained were
compared with the nonredundant sequence data bases present at the
National Center for Biotechnology Information using the BLAST network
service. Multiple amino acid sequence alignment was performed using the
Parallel Protein Information Analysis system (41) (Parallel Application
TRC Laboratory, Real World Computing Partnership, Tsukuba, Japan).
Protein sorting signals and subcellular localization were predicted
using the PSORT World Wide Web server (42).
Expression of Mouse Ganglioside Sialidase cDNA in COS-1
Cells--
To construct the sialidase expression plasmid, a set of
primers, 10S (5'-CCCGAATTCGCCATGGAGGAAGTCCCA-3') and 11A
(5'-CCCGAATTCTTAGTCGCTACTAGGGCT-3'), both containing EcoRI
restriction sites at the 5' end, was used to amplify the sequence
encoding the entire open reading frame, including the Kozak sequence
(43), with the template cDNA synthesized from mouse brain
poly(A)+ RNA. After digestion with EcoRI, PCR
products were ligated into the EcoRI site of the pME18S
eukaryotic expression vector. The presence, orientation, and fidelity
of the cDNA in the vector were confirmed by digestion of
restriction enzyme and DNA sequencing. To verify the
ganglioside-hydrolyzing sialidase activity, COS-1 cells (Riken Cell
Bank) were transfected by electroporation with the empty expression
vector or the expression vector containing the mouse ganglioside
sialidase cDNA by the following procedures. Cells washed twice with
phosphate-buffered saline (PBS) were resuspended in HEPES-PBS at a
final concentration of 1.0 × 107 cells/ml, and an
aliquot of the suspension (750 µl) was added to sterile cuvettes with
40 µg of plasmid DNA. The cuvette was placed on ice for 10 min and
electroporated at 240 V, 975 µF using a Bio-Rad Genepulser. The
cuvette was placed on ice for an additional 10 min, and cells were
cultured in 40 ml of Dulbecco's modified Eagle's medium (DMEM)
supplemented with penicillin (100 IU/ml), streptomycin (100 µg/ml),
and 10% heat-inactivated fetal bovine serum. After 48 h, cells
were pelleted, lysed in 9 volumes of ice-cold PBS by sonication, and
centrifuged at 1000 × g at 4 °C for 10 min. The
supernatant (crude homogenate) was further centrifuged at 100,000 × g at 4 °C for 1 h. The resulting supernatant and pellet were used as cytosolic and membrane fractions, respectively, and
were assayed for sialidase activity with various substrates that
included gangliosides. Stable transfectants of the sialidase were
obtained using mouse neuroblastoma Neuro2a cells (American Type Culture
Collection, CCL-131), cultured in DMEM containing high glucose
supplemented with penicillin, streptomycin, and 10% fetal bovine
serum. After overnight culture at 2 × 105 cells per
35-mm culture dish, cells at 50-60% confluence were washed with
serum-free medium and then incubated with a DNA (2 µg)-PLUS (6 µl)-LipofectAMINE (8 µl) (Life Technologies, Inc.) reagent complex
for 5 h. At 48 h after lipofection, selection started in
growth medium containing 500 µg/ml G418 (Life Technologies, Inc.).
Following 5 weeks of selection, discrete colonies were subcloned and expanded.
Sialidase Assay--
Sialidase activity was assayed using
various substrates as described elsewhere (27). Briefly, the reaction
mixture contained 30 nmol of substrate as bound sialic acid, 0.2 mg of
bovine serum albumin, 10 µmol of sodium acetate (pH 4.6), and 0.2 mg
of Triton X-100. After incubation at 37 °C for 10-30 min, released
sialic acid was determined by the thiobarbituric acid method of Aminoff (44). Sialidase activity toward 4-methylumbelliferyl-neuraminic acid
was assayed by spectrofluorometrical measurement of
4-methylumbelliferone released. To determine the pH profile of the
activity, HEPES, 2-morpholinoethanesulfonic acid, and citrate-phosphate
buffers also were used. One unit of sialidase was defined as the amount of enzyme that catalyzed the release of 1 nmol of sialic acid/h.
Analyses of Cellular Sialic Acids and Glycolipids--
Cells
(107) harvested at subconfluency were washed with PBS and
lyophilized. The glycolipids were extracted in sequence with 5 ml of
chloroform/methanol (C/M) (1:1, v/v), 2.5 ml of C/M (2:1, v/v), and 2.5 ml of C/M (1:2, v/v), and then evaporated to dryness. After desalting
by dialysis, the glycolipids were again lyophilized and dissolved in a
small volume of C/M (2:1, v/v), and one-tenth of the amount was
chromatographed on high performance thin layer chromatographic plates
(Baker, Phillipsburg, NJ) in C/M/0.5% CaCl2 (60:40:9,
v/v/v). Glycolipids were visualized with the
orcinol-H2SO4. To determine the cellular sialic
acids, the glycolipid extracts (lipid-bound sialic acid) and the
residues after extraction (protein-bound sialic acid) were treated in
0.1 N H2SO4 at 80 °C for 1 h and assayed for sialic acids. To estimate small amounts of sialic acids, fluorometric high performance liquid chromatography with 1,2-diamino-4,5-methylene dioxybenzene was employed (45).
BrdUrd-induced Neuritogenesis in Neuro2a Cells--
Neuro2a
cells were initially grown in DMEM with penicillin, streptomycin, and
5% fetal bovine serum, with cell passage every 2-3 days. They were
seeded in 150-cm2 sterile tissue culture flasks at a
density of 2 × 104/cm2. After overnight
incubation in the above medium, cells were exposed for variable periods
(0-5 days) to 0.25 mM BrdUrd (46). The morphology of the
cells was examined, and photographs were taken at × 100 magnification. To quantify neuritogenesis, five randomly chosen fields
in each flask were counted, and cells bearing neurites at least
1.5-fold the length of the soma diameter were considered as
differentiated. All of the cells collected were assayed for sialidase
activity using bovine brain mixed gangliosides as substrates and for
acetylcholinesterase activity using the spectrophotometric procedure
described by Ellman et al. (47).Total RNAs were extracted for quantitative PCR by the acid guanidium-phenol-chloroform extraction procedure (39).
Preparation of Deleted cDNA and Quantitative RT-PCR--
To
evaluate the mRNA level of the sialidase in variously
differentiated Neuro2a cells, we adopted competitive PCR methods (48)
using the deleted mouse sialidase cDNA clone as a competitor. The
competitor cDNA was prepared by double-digestion of the mouse sialidase cDNA encoding the entire open reading frame in Bluescript vector with MunI and BbsI. From 5 µg of total
RNA, cDNA was synthesized using 200 units of MoMuLV-RT and
oligo(dT) primers in a final volume of 20 µl. 10 µl of the
25-fold-diluted solution was subjected to quantitative PCR analysis.
PCR amplifications were performed with a set of primer pairs 12S
(5'-GCCATGGAGGAAGTCCCA-3') and 13A (5'-TTAGTCGCTACTAGGGCT-3') under the
following conditions: 1 min at 94 °C, 1 min at 54 °C, and 2 min
at 72 °C for 40 cycles, preceded by 10 min at 95 °C and followed
by 10 min at 72 °C, generating a 1254-bp product from the target
cDNA and a 937-bp product from the competitor cDNA. The
quantitative PCR analysis consisted of two steps: the first PCR for
rough measurement using 10 fg of competitor DNA, and the second PCR for
precise quantification based on the amount of target DNA estimated from
the first PCR. To check for sample-to-sample variation, the expression
level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (49) was measured for each cDNA sample using a GAPDH competitor, prepared by
digestion of the 0.5-kilobase cDNA (nucleotides 566-1017) with StyI and BspMI. After amplification, 10-µl
aliquots were electrophoresed in 1% agarose gels, followed by
photographic recording of the gels stained with ethidium bromide. Gel
photos were scanned and densitometric analyses of PCR products were
performed using the image analysis program NIH Image, version 1.61 (Research Services Branch, NIMH, National Institutes of Health). Under
the PCR conditions, a linear correlation between the densitometry
intensity and amount of template was also confirmed using standard cDNAs.
Northern Blot Analysis--
Mouse multiple tissue Northern blots
(CLONTECH) were hybridized with an
[
-32P]dCTP-labeled MBIIA fragment amplified by the
polymerase chain reaction, according to the manufacturer's
specifications. After overnight incubation at 42 °C, membranes were
washed twice in 2× SSC, 0.1% SDS at 42 °C for 30 min and used to
expose imaging plates. The radioactivity was visualized with an Image
Analyzer BAS2000 system (Fuji Photo Film). The tissue mRNA level
was further estimated by quantitative RT-PCR methods as described above.
In Situ Hybridization--
The mouse sialidase cDNA fragment
stretching from base 374 to 769 was cloned into the Bluescript vector
in the correct orientation. To generate sense and antisense probes, the
plasmids were then linearized by HindIII and XbaI
and transcribed by T3 and T7 RNA polymerase, respectively, in the
presence of digoxigenin-labeled UTP (Roche Molecular Biochemicals).
Probes were fragmented to approximately 150 bp in length by alkaline
treatment before use. Sagittal sections (15-µm) of brain from a
7-week-old BALB/c mouse were cut on a Micron cryostat at
20 °C and
thaw-mounted onto silane coated slides. The sections were fixed in 4%
paraformaldehyde plus 0.5% glutaraldehyde/PBS and incubated with 10 µg/ml proteinase K for 30 min at 37 °C. After acetylation with
0.25% acetic anhydride for 10 min in room temperature, the sections
were dehydrated and prehybridized for 1 h at 48 °C in a
hybridization buffer consisting of 50% deionized formamide, 4× SSC,
20% dextran sulfate, 1× Denhardt's solution, and 0.25 mg/ml yeast
tRNA. They were then incubated with an antisense riboprobe (or a sense
probe as a negative control) at 48 °C overnight in a humidified box
followed by successive incubations in 2× SSC at 48 °C for 15 min
twice, in 2× SSC with 100 µg/ml RNaseA at 37 °C for 30 min, and
in 0.1× SSC at room temperature for 10 min. Positive signals were
detected by immunoassay with anti-digoxigenin-alkaline phosphatase
conjugate and the color substrates NBT/X-phosphate (Roche Molecular Biochemicals).
 |
RESULTS |
The PCR with primers designed on the basis of conserved amino acid
sequences between bovine membrane and rat cytosolic sialidases yielded
a specific product MBI of 240 bp showing 80% amino acid sequence
identity with the bovine sialidase. PCR with degenerate primers from
the sequence conserved between human membrane and human lysosomal
sialidases gave 380- and 420-bp products, the deduced amino acid
sequences of which were highly homologous to the lysosomal and membrane
sialidases, respectively. Sequencing analyses of the 420-bp products
revealed the presence of two distinct amplicon sequences, MBIIA and
MBIIB. The deduced amino acid sequence of MBIIA showed 80% identity to
the corresponding region of the bovine membrane sialidase and included
the MBI sequence obtained as described above. On the other hand, the
sequence of MBIIB was completely identical to the human membrane
sialidase. Northern blot analysis by MBIIA probe revealed the presence
of a hybridizing transcriptant of approximately 3.4 kilobases in mouse
brain as described below, but the MBIIB probe showed a 2.4-kilobase
faint band that disappeared under relatively high stringency
conditions. Genomic Southern blot experiments using MBIIA and MBIIB
probes demonstrated two genomic patterns indistinguishable from each other (data not shown). Although these results cannot exclude the
possible presence of two types of putative membrane sialidases in mouse
brain, we decided to obtain a mouse major membrane sialidase cDNA
by the RACE methods based on the nucleotide sequence of MBIIA. 5'-RACE
generated six positive products (312-433 bp) after two rounds of PCR
amplification, the sequences of which were found to overlap with each
other. A single 2646-bp product obtained by 3'-RACE contained the 3'
end of MBIIA and two Asp boxes, known to be the consensus sequences for
sialidases (50). These two cDNAs were used to construct a cDNA
encoding the entire sequence (3339 bp) of the mouse sialidase, as shown
in Fig. 1. An in-frame stop codon (TGA,
nucleotides 11-13) was found located upstream of the first methionine
codon (nucleotides 266-268), and the sequence surrounding the
translation start site fit reasonably well with the Kozak consensus
(43). The 3'-untranslated region contained the polyadenylation signal
(AATAAA), 18 bases upstream from the poly(A) tail. The predicted open
reading frame encodes a protein of 418 amino acids with a calculated
molecular mass of 46.8 kDa. Protein and nucleotide data base homology
searches revealed that the mouse sialidase has significant homology
with mammalian, bacterial, and viral sialidases. Among mammalian
sialidases so far cloned, the highest homology was detected with the
bovine and human plasma membrane-associated sialidase (31, 32) (67.1 and 67.8%, respectively), and lower but still significant similarity
was found with mouse (51), rat (30), and human (52) cytosolic
sialidases (40.4, 39.4, and 39.8%, respectively). There were less
significant sequence identities with human (33-35) and mouse (36-38)
lysosomal sialidases (29.0 and 26.4%, respectively). A multiple
alignment of the amino acid sequences of the mouse sialidase and other
mammalian sialidases is shown in Fig. 2.
The sequence motif (F/Y)RIP (amino acids 24-27), which is highly
conserved near the N terminus of all of the sialidases described thus
far, and three copies
(SEDAGCSW, amino acids
131-138; SDDFGVTW, amino acids 203-210; and STDSGGCF, amino
acids 254-261) of Asp boxes are present in the mouse sialidase. There is a putative hydrophobic segment at 174-194 split by an internal arginine but neither a potential site of N-glycosylation nor
an affirmative sorting signal. Northern blot analysis revealed a transcript of approximately 3.4 kilobases (Fig.
3A) expressed most highly in
heart but also in brain, spleen, lung, kidney, and testis. Further
estimation of the mRNA level by competitive RT-PCR methods provided
evidence that brain, especially cerebellum, is rich in this sialidase,
as well as heart (Fig. 3B). Determination of the spatial
localization of the sialidase mRNA in adult mouse brain by in
situ hybridization analysis revealed positive signals mainly in
the layers II-IV of cerebral cortex and the granule cell layer,
Purkinje cells, and deep cerebellar nucleus of the cerebellum (Fig.
4). The signal intensity with the
antisense probe in the hippocampal formation was slightly higher than
with the sense probe (data not shown).


View larger version (38111K):
[in this window]
[in a new window]
|
Fig. 1.
Nucleotide and deduced amino acid sequences
of the mouse ganglioside sialidase. The predicted amino acid
sequence is shown by the single letter amino acid code under the
nucleotide sequence. The polyadenylation signal is
underlined, the Asp boxes are boxed, and the YRIP
motif is indicated by a dotted line.
|
|

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 2.
Amino acid sequence alignment of mammalian
sialidases. Alignment of the entire amino acid sequences of the
mouse ganglioside sialidase (Mus GangSD) with the sequences
of the bovine plasma membrane (28) (Bov PlasSD), mouse
cytosolic (Mus CytoSD), rat cytosolic (26) (Rat
CytoSD), and mouse lysosomal (32) (Mus LysoSD)
sialidases. Conserved amino acid residues are indicated by filled
boxes. The Asp boxes are solid underlined and F/YRIP
motif is double underlined. Dashes indicate gaps
introduced by the Parallel Protein Information Analysis algorithm to
maximize alignment (42).
|
|

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 3.
Analysis of the ganglioside sialidase
mRNA expression in various mouse tissues. A, a
mouse multiple tissue Northern blot (CLONTECH) was
hybridized with an [ -32P]dCTP-labeled sialidase
cDNA (nucleotides 374-769). RNA sizes in kilobases (kb)
were determined relative to a RNA ladder. B, the RNA level
in mouse brain, heart, and skeletal muscle was determined by
competitive PCR as described under "Experimental Procedures."
Expression of GAPDH was also measured to check for sample-to-sample
variation. Gel photos were scanned and densitometric analysis was
performed using the image analysis program NIH Image, version
1.61.
|
|

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 4.
In situ hybridization analysis of
the ganglioside sialidase in adult mouse brain. Frozen
parasaggital sections of a BALB/c mouse brain were hybridized with
digoxigenin-labeled ganglioside sialidase antisense (A and
C) and sense (B and D) RNAs.
A and B, cerebral cortex; C and
D, cerebellum. All of the photographs were taken at × 100 magnification.
|
|
To confirm that the isolated cDNA clone encodes a functionally
active sialidase, expression plasmids (pMEmmSD) under the SR
promoter were transiently transfected into COS-1 cells. The
pMEmmSD-transfected cells showed an increase of 1500-fold in sialidase
activity toward gangliosides in the presence of 0.1% Triton X-100 as
compared with untransfected cells or with vector-transfected cells
(Fig. 5). Over 85% of the expressed
sialidase activity in the crude homogenates was recovered in the
particulate fraction, suggesting a membrane-bound form. Table
I summarizes the substrate specificity of
the expressed sialidase. The sialidase hydrolyzed gangliosides GD3,
GM3, GD1a preferentially and also oligosaccharides, such as
2
3
sialyllactose, to some degree, with optimum pH at 4.1-4.5. When the
kinetic properties of the sialidase were compared using GM3, GD1a, and
sialyllactose as substrates, the Km for sialyllactose (584 µM) was found to be 10 times higher
than the values for GM3 (47 µM) and GD1a (57 µM), indicating that gangliosides are able to be
hydrolyzed much more efficiently than sialyllactose by the sialidase.
Computer sequence analysis by PSORT World Wide Web server predicted
that the polypeptide might be localized in microsomes.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of the ganglioside sialidase in
COS-1 cells. Sialidase activity in cells 2 days after pMEmmSD
transfection by electroporation. Cells were collected and assayed using
mixed gangliosides as substrates.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Sialidase activities toward various substrates in the homogenates of
COS-1 cells transfected with the mouse ganglioside sialidase cDNA
|
|
To investigate an involvement of the ganglioside sialidase in the
differentiation of neuronal cells, we measured levels of sialidase
activity (Fig. 6A) and
mRNA (Fig. 7) in Neuro2a cells differentiated by BrdUrd. The total cell numbers increased only slightly at 2-3 days of BrdUrd treatment, and there were 10-15% dead
cells in the culture medium at 4-5 days. As the proportion of cells
bearing neurites rose to 65% by 4 days, elevation of ganglioside
sialidase activity was observed, with a concomitant increase of
acetylcholinesterase (Fig. 6B), a neuronal differentiation marker, indicating that BrdUrd causes functional as well as
morphological differentiation of murine neuroblastoma cells. Successive
quantitative PCR analyses showed an increase of over 10-fold in the
amount of transcripts observed after 3 days of treatment and a 21-fold increase after another 2 days, as compared with the untreated cell case
(Fig. 7), equal amounts of template cDNA being confirmed by means
of GAPDH.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Ganglioside sialidase activity during
BrdUrd-induced differentiation of Neuro2a cells. Neuro2a cells
were seeded at a density of 2 × 104
cells/cm2 in DMEM supplemented with 0.25 mM
BrdUrd. At the indicated day, the number of neurite-bearing cells was
counted (A, ), cells were harvested by trypsinization,
and the homogenates were assayed for ganglioside sialidase (A,
black bars) and acetylcholinesterase activities (B),
respectively.
|
|

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 7.
Quantitative measurement of the ganglioside
sialidase mRNA in BrdUrd-stimulated Neuro2a cells. Neuro2a
cells were seeded at a density of 2 × 104/cm2 in medium containing 0.25 mM BrdUrd. At the indicated day, cells were harvested for
total RNA preparation. The mRNA expression of each samples
was quantified by competitive PCR using deleted cDNA competitors,
as described in Fig. 3.
|
|
To further elucidate the functional role of ganglioside sialidase in
the process of neuronal differentiation, Neuro2a cells were stably
transfected with the expression plasmid. Three independent positive
clones showed markedly increased levels of ganglioside sialidase
activity (Fig. 8A). Two of the
three clones appeared morphologically indistinguishable from parental
Neuro2a cells, but the stable transfectant Neuro-mSD10 with the highest
activity (about 18-fold versus control cells) had more
neurites compared with the parental cells. All three clones showed
accelerated neurite outgrowth on BrdUrd treatment: 45, 40, and 36% of
the transfectants Neuro-mSD10, -2, and -16, in the order of activity
level, respectively, bore neurites more than 1.5-fold longer than the
soma diameter at day 2 (Fig. 8B). Consequently there seemed
to be a correlation between ganglioside-hydrolyzing activity and
acceleration of neurite outgrowth. Unlike the sialidase-overexpressing
cells, less than 15% of the parental Neuro2a cells contained neurites
at day 1 and 31% at day 2. At day 3, more than 44% of both parental
and sialidase-transfected Neuro2a cells had neurites. It should be noted that the length and complexity of neurites in the
sialidase-transfected Neuro2a cells appeared longer and greater than
those of parental Neuro2a cells.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of overexpression of the ganglioside
sialidase cDNA on neuro2a cell differentiation induced by
BrdUrd. A, Neuro2a cells were stably transfected with
the expression construct pMEmmSD as described under "Experimental
Procedures." Three independent positive clones (Neuro-mSD2,
Neuro-mSD10, and Neuro-mSD16) showed high levels of ganglioside
sialidase activity compared with parental (Neuro2a) and empty
vector-transfected (Neuro-neo) cells. B, cells were cultured
in medium containing 0.25 mM BrdUrd, and photographs were
taken at × 100 magnification on the day indicated. To determine
the effect of sialidase gene expression, cells were counted and scored
for the expression of neurites at least 1.5-fold the diameter of the
soma.
|
|
In confirmation of an direct involvement of the sialidase in neurite
formation through desialylation of gangliosides, we observed changes in
cellular sialic acid contents and ganglioside patterns that the
sialidase would bring about. Lipid-bound sialic acids of the cells
(106) were determined to be 0.83, 1.0, and 0.23 nmol,
whereas protein-bound sialic acids were 2.81, 2.74, and 2.76 nmol in
parental Neuro2a cells, Neuro-neo, and Neuro-mSD10, respectively. These
data indicate that the overexpressing sialidase desialylates
specifically gangliosides, consistent with the results on its substrate
specificity. Ganglioside patterns by thin layer chromatography revealed
that GM3 (55-60%), GM2 (23-27%), and GD1a (10-14%) were found to
be major gangliosides in the cells, and a decrease in these
gangliosides was observed in the sialidase-overexpressing cells. After
BrdUrd treatment, a small amount of GM1(1.5-2% of the total
gangliosides) became apparent in these cells, and the percentage of GM1
was two times higher in the sialidase-transfected cells than in the
control cells.
 |
DISCUSSION |
In this study, we report cDNA cloning and expression for a
mouse ganglioside sialidase with a YRIP sequence and Asp boxes playing
a major role in ganglioside degradation in the neuronal system. Thus
transfection of the cDNA into COS-1 cells led to a marked increase
of sialidase activity with ganglioside substrate preference. When
neurite outgrowth of Neuro2a cells was stimulated by BrdUrd, the
enzymatic and transcriptional activities of the sialidase were
strikingly enhanced in proportion to neurite arborization, and
transfection of the sialidase cDNA into Neuro2a cells resulted in
accelerated neurite outgrowth.
The observed similarity of primary structure and enzymatic properties
to bovine and human membrane sialidases argues that the ganglioside
sialidase represents the mouse homolog of these sialidases (31, 32).
Degenerate PCR amplification suggested a possible presence of another
ganglioside sialidase with very low expression, at least partially
identical to the human membrane sialidase. In addition, a cytosolic
sialidase could be considered as an another sialidase responsible for
ganglioside degradation (27, 30).We thus identified a cDNA for a
mouse cytosolic sialidase from mouse skeletal muscle by the
homology-based RT-PCR and RACE methods as shown in the multiple
alignment (Fig. 2). The primary structure was found to be 88%
identical to that of rat cDNA. Compared with the nucleotide
sequence of the mouse cDNA recently reported (51), our cDNA
sequence differs in several nucleotides, leading to amino acid
differences in both the N and C termini. Measurement of expression
levels by RT-PCR gave values over 10 times higher for the membrane than
the cytosolic sialidase in mouse brain (data not shown). These data
strongly suggest that the membrane sialidase cloned here may be the
major ganglioside sialidase in mouse brain and Neuro2a cells. The
substrate specificity of this sialidase for ganglioside preference and
the fact that the transfection of the membrane sialidase resulted only
in a decrease of glycolipid-bound sialic acids also support the idea
that the sialidase expression in neuronal cells is associated with
specific desialylation of gangliosides compared with other
sialoglycoconjugates. In situ hybridization analysis
revealed interesting results consistent with ganglioside expression
patterns previously reported by other investigators. Regional
differences in ganglioside composition have been described in mammalian
brain (53, 54), and immunological analysis of rat brain has suggested a
cell- and layer-specific expression of major and minor gangliosides.
GM3 is expressed intensely in the white matter and only slightly in the
granular layer of the rat cerebellar cortex; GD3 in both the granular
layer and the white matter, as well as in the cerebral cortex; and GD1a exclusively in layers I, II/III, and Va, as well as the upper part of
layer VI. Our in situ hybridization analysis showed an mRNA pattern strikingly similar to the ganglioside expression pattern of rat brain. The physiological significance of this sialidase in heart, its site of highest expression on Northern blotting, is
uncertain. It might play a role in the regulation of myocardial Ca2+ channel function, because it has been reported that
bacterial sialidase selectively enhances transient Ca2+
currents in cardiac myocytes (55).
Modulation of endogenous gangliosides has been shown to influence the
process of neuronal differentiation. For example, treatment of Neuro2a
cells with cholera toxin B-subunit and anti-GM1 antibody inhibited
neurite outgrowth (19), whereas anti-GM3 stimulated differentiation
(56). Transfection of Neuro2a cells with ganglioside GD3 synthase
cDNA increases the amount, not of only GD3, but also of b-series
gangliosides, resulting in changes in cell morphology, along with
cholinergic differentiation (57). Neurite outgrowth from murine
neuroblastoma cells has been found to be significantly inhibited by
threo-1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol, an
effective inhibitor of glycosphingolipid synthesis (58). Sialidases and
specific inhibitors have proven to be useful tools for alteration of
ganglioside patterns on the neuronal surface, and modification of
de novo degradation of gangliosides may affect cellular
differentiation. This sialidase inhibitor,
2,3-dehydro-2-deoxy-N-acetylneuraminic acid, abolished
increase of neuronal differentiation marker acetylcholinesterase in a
human neuroblastoma cell line (20, 21). In granule cells from rat
cerebellum, a marked increase of sialidase activity is observed during
differentiation with formation of functional synapses (18). Exogeneous
bacterial sialidase from Clostridium perfringens stimulates
neurite outgrowth in murine neuroblastoma cells (19). Bacterial
sialidase-induced neuritogenesis is closely related to the alteration
of intracellular calcium homeostasis secondary to the up-regulation of
GM1 on the cell surface and nuclear envelope (59).
Together with these previous reports, our experiments on Neuro2a cells
provide direct evidence of crucial role of the ganglioside sialidase in
neurite formation. The sialidase expression may affect the rate of
which cell express neurites rather than the overall extent because the
transfection effects are observed at earlier times. As GD1a, GM3, and
GM2 were found to be major gangliosides in the cells, which is
consistent with previous reports (46, 60), and as they were good
substrates for the sialidase except for GM2 (as shown in Table I),
quantitative and qualitative changes of these gangliosides may occur
with increased expression of the sialidase during neurite formation.
Our present study confirmed that one of the characteristic features is
an appearance of GM1, which is likely to occur by increased expression
of the sialidase. A GM2-hydrolyzing sialidase activity has been
reported (28, 61, 62) in rodents and canine cells, but the enzyme(s)
seems to be distinct from our sialidase. Our preliminary data suggest that sialidase activity toward GM2 gradually rises, but only a 1.7-fold
increase was noted even at day 3 of BrdUrd treatment, suggesting
only a limited involvement in BrdUrd-induced neuritogenesis.
In conclusion, the results of the present study indicate that a
membrane ganglioside sialidase is important for neuronal cell differentiation. Although the regulation mechanisms are not fully understood at present, it is feasible that the sialidase is modulated by various kinases, including protein kinase C (63), as well as
controlled at the gene transcription level. This sialidase, on the
other hand, would give an influence on signal transduction processes by
alteration of gangliosides affecting various kinase activities
(64-66). Taken together, our experiments provide strong evidence for
an essential participation of the sialidase in ganglioside modulation
in the central nervous system and in neuroblastoma cells.
 |
ACKNOWLEDGEMENTS |
We are grateful to Dr. Kazuo Maruyama, Tokyo
Medical and Dental University, for kindly providing the pME18S vector
and to Dr. Masashi Sawada, Tohoku University School of Medicine, for helpful discussion. We also thank Hiroyuki Kato and Setsuko Moriya, Divisions of Pathology and Biochemistry, respectively, Miyagi Prefectural Cancer Center, for expert technical assistance.
 |
FOOTNOTES |
*
This work was supported in part by a grant-in-aid for
scientific research on priority areas from the Ministry of Education, Science, Sports and Culture of Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AB026842 and AB008184 for mouse membrane-associated
ganglioside sialidase and mouse cytosolic sialidase, respectively.
¶
To whom correspondence should be addressed. Tel.:
81-22-384-3151; Fax: 81-22-381-1195; E-mail:
tmiyagi@mcc.pref.miyagi.jp.
 |
ABBREVIATIONS |
The abbreviations used are:
BrdUrd, 5-bromodeoxyuridine;
RACE, rapid amplification of cDNA ends;
PCR, polymerase chain reaction;
PBS, phosphate-buffered saline;
DMEM, Dulbecco's modified Eagle's medium;
RT, reverse transcription;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
bp, base pair(s);
C/M, chloroform/methanol.
 |
REFERENCES |
| 1.
|
Svennerholm, L.
(1963)
J. Neurochem.
10,
613-623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Wiegandt, H.
(1967)
J. Neurochem.
14,
671-674[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Purpura, D. P.,
and Baker, H. J.
(1977)
Nature
266,
553-554[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Roisen, F. J.,
Bartfeld, H.,
Nagele, R.,
and Yorke, G.
(1981)
Science
214,
577-578[Abstract/Free Full Text]
|
| 5.
|
Rahmann, H.
(1983)
Neurochem. Int.
5,
539-547[CrossRef]
|
| 6.
|
Ferrari, G.,
Anderson, B. L.,
Stephens, R. M.,
Kaplan, D. R.,
and Greene, L. A.
(1995)
J. Biol. Chem.
270,
3074-3080[Abstract/Free Full Text]
|
| 7.
|
Skaper, S. D.
(1994)
Glycobiology and the Brain
, pp. 213-228, Pergamon Press, Oxford, United Kingdom
|
| 8.
|
Hakomori, S.
(1993)
Biochem. Soc. Trans.
21,
583-595
|
| 9.
|
Vanier, M. T.,
Holm, M.,
Öhman, R.,
and Svennerholm, L.
(1971)
J. Neurochem.
18,
581-592[Medline]
[Order article via Infotrieve]
|
| 10.
|
Svennerholm, L.,
Boström, K.,
Fredman, P.,
Månsson, J.-E.,
Rosengren, B.,
and Rynmark, B.-M.
(1989)
Biochim. Biophys. Acta
1005,
109-117[Medline]
[Order article via Infotrieve]
|
| 11.
|
Li, R.,
and Ladisch, S.
(1992)
J. Neurochem.
59,
2297-2303[Medline]
[Order article via Infotrieve]
|
| 12.
|
Schubert, D.,
and Jacob, F.
(1970)
Proc. Natl. Acad. Sci. U. S. A.
67,
247-254[Abstract/Free Full Text]
|
| 13.
|
Ihara, Y.,
Nishikawa, A.,
and Taniguchi, N.
(1995)
Glycoconj. J.
12,
787-794[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Facci, L.,
Leon, A.,
Toffano, G.,
Sonnino, S.,
Ghidoni, R.,
and Tettamanti, G.
(1984)
J. Neurochem.
42,
299-305[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Ferrari, G.,
Fabris, M.,
and Gorio, A.
(1983)
Dev. Brain Res.
8,
215-221[CrossRef]
|
| 16.
|
Cuello, A. C.,
Garofalo, L.,
Kenigsberg, R. L.,
and Maysinger, D.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
2056-2060[Abstract/Free Full Text]
|
| 17.
|
Tsuji, S.,
Arita, M.,
and Nagai, Y.
(1983)
J. Biochem.
94,
303-306[Abstract/Free Full Text]
|
| 18.
|
Pitto, M.,
Chigorno, V.,
Giglioni, A.,
Valsecchi, M.,
and Tettamanti, G.
(1989)
J. Neurochem.
53,
1464-1470[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Wu, G.,
and Ledeen, R. W.
(1991)
J. Neurochem.
56,
95-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Kopitz, J.,
von Reitzenstein, C.,
Mühl, C.,
and Cantz, M.
(1994)
Biochem. Biophys. Res. Commun.
199,
1188-1193[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Kopitz, J.,
von Reitzenstein, C.,
Sinz, K.,
and Cantz, M.
(1996)
Glycobiology
6,
367-376[Abstract/Free Full Text]
|
| 22.
|
Saito, M.,
and Yu, R. K.
(1992)
J. Neurochem.
58,
83-87[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Saito, M.,
Tanaka, Y.,
Tang, C.-P., Yu, R. K.,
and Ando, S.
(1995)
J. Neurosci. Res.
40,
401-406[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Schengrund, C.-L.,
and Rosenberg, A.
(1970)
J. Biol. Chem.
245,
6196-6200[Abstract/Free Full Text]
|
| 25.
|
Yohe, H. C.,
and Rosenberg, A.
(1977)
J. Biol. Chem.
252,
2412-2418[Abstract/Free Full Text]
|
| 26.
|
Miyagi, T.,
and Tsuiki, S.
(1984)
Eur. J. Biochem.
141,
75-81[Medline]
[Order article via Infotrieve]
|
| 27.
|
Miyagi, T.,
and Tsuiki, S.
(1985)
J. Biol. Chem.
260,
6710-6716[Abstract/Free Full Text]
|
| 28.
|
Miyagi, T.,
Sagawa, J.,
Konno, K.,
Handa, S.,
and Tsuiki, S.
(1990)
J. Biochem.
107,
787-793[Abstract/Free Full Text]
|
| 29.
|
Hata, K.,
Wada, T.,
Hasegawa, A.,
Kiso, M.,
and Miyagi, T.
(1998)
J. Biochem.
123,
899-905[Abstract/Free Full Text]
|
| 30.
|
Miyagi, T.,
Konno, K.,
Emori, Y.,
Kawasaki, H.,
Suzuki, K.,
Yasui, A.,
and Tsuiki, S.
(1993)
J. Biol. Chem.
268,
26435-26440[Abstract/Free Full Text]
|
| 31.
|
Miyagi, T.,
Wada, T.,
Iwamatsu, A.,
Hata, K.,
Yoshikawa, Y.,
Tokuyama, S.,
and Sawada, M.
(1999)
J. Biol. Chem.
274,
5004-5011[Abstract/Free Full Text]
|
| 32.
|
Wada, T.,
Yoshikawa, Y.,
Tokuyama, S.,
Kuwahara, M.,
Akita, H.,
and Miyagi, T.
(1999)
Biochem. Biophys. Res. Commun.
261,
21-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Bonten, E.,
van der Spoel, A.,
Fornerod, M.,
Grosveld, G.,
and d'Azzo, A.
(1996)
Genes Dev.
10,
3156-3169[Abstract/Free Full Text]
|
| 34.
|
Milner, C. M.,
Smith, S. V.,
Carrillo, M. B.,
Taylor, G. L.,
Hollinshead, M.,
and Campbell, R. D.
(1997)
J. Biol. Chem.
272,
4549-4558[Abstract/Free Full Text]
|
| 35.
|
Pshezhetsky, A. V.,
Richard, C.,
Michaud, L.,
Igdoura, S.,
Wang, S.,
Elsliger, M.-A.,
Qu, J.,
Leclerc, D.,
Gravel, R.,
Dallaire, L.,
and Potier, M.
(1997)
Nat. Genet.
15,
316-320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Carrillo, M. B.,
Milner, C. M.,
Ball, S. T.,
Snoek, M.,
and Campbell, R. D.
(1997)
Glycobiology
7,
975-986[Abstract/Free Full Text]
|
| 37.
|
Igdoura, S. A.,
Gafuik, C.,
Mertineit, C.,
Saberi, F.,
Pshezhetsky, A. V.,
Potier, M.,
Trasler, J. M.,
and Gravel, R. A.
(1997)
Hum. Mol. Genet.
7,
115-121[Abstract/Free Full Text]
|
| 38.
|
Rottier, R. J.,
Bonten, E.,
and d'Azzo, A.
(1998)
Hum. Mol. Genet.
7,
313-321[Abstract/Free Full Text]
|
| 39.
|
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
|
| 40.
|
Frohman, M. A.,
Dush, M. K.,
and Martin, G. R.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
8998-9002[Abstract/Free Full Text]
|
| 41.
|
Akiyama, Y.,
Onizuka, K.,
Noguchi, T.,
and Ando, M.
(1998)
Proceedings of the 9th Genome Informatics Workshop
, pp. 131-141, Universal Academy Press, Tokyo
|
| 42.
|
Nakai, K.,
and Horton, P.
(1999)
Trends Biochem. Sci.
24,
34-36[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Kozak, M.
(1989)
J. Cell. Biol.
108,
229-241[Abstract/Free Full Text]
|
| 44.
|
Aminoff, D.
(1961)
Biochem. J.
81,
384-392[Medline]
[Order article via Infotrieve]
|
| 45.
|
Hara, S.,
Yaguchi, M.,
Takemori, Y.,
and Nakamura, M.
(1986)
J. Chromatogr.
377,
111-119[Medline]
[Order article via Infotrieve]
|
| 46.
|
Chatterjee, D.,
Chakraborty, M.,
and Anderson, G. M.
(1992)
Brain Res.
583,
31-44[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Ellman, G. L.,
Courtney, K. D.,
Andres, V., Jr.,
and Featherstone, R. M.
(1961)
Biochem. Pharmacol.
7,
88-95[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Gilliland, G.,
Perrin, S.,
Blanchard, K.,
and Bunn, H. F.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
2725-2729[Abstract/Free Full Text]
|
| 49.
|
Sabath, D. E.,
Broome, H. E.,
and Prystowsky, M. B.
(1990)
Gene
91,
185-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Roggentin, P.,
Rothe, B.,
Kaper, J. B.,
Galen, J.,
Lawrisuk, L.,
Vimr, E. R.,
and Schauer, R.
(1989)
Glycoconj. J.
6,
349-353[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Fronda, C. L.,
Zeng, G.,
Gao, L.,
and Yu, R. K.
(1999)
Biochem. Biophys. Res. Commun.
258,
727-731[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Monti, E.,
Preti, A.,
Rossi, E.,
Ballabio, A.,
and Borsani, G.
(1999)
Genomics
57,
137-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Kotani, M.,
Kawashima, I.,
Ozawa, H.,
Terashima, T.,
and Tai, T.
(1993)
Glycobiology
3,
137-146[Abstract/Free Full Text]
|
| 54.
|
Kotani, M.,
Kawashima, I.,
Ozawa, H.,
Ishizuka, I.,
Terashima, T.,
and Tai, T.
(1994)
Glycobiology
4,
855-865[Abstract/Free Full Text]
|
| 55.
|
Yee, H. F., Jr.,
Weiss, J. N.,
and Langer, G. A.
(1989)
Am. J. Physiol.
256,
C1267-C1272[Abstract/Free Full Text]
|
| 56.
|
Spirman, N.,
Sela, B.-A.,
and Schwartz, M.
(1982)
J. Neurochem.
39,
874-877[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Kojima, N.,
Kurosawa, N.,
Nishi, T.,
Hanai, N.,
and Tsuji, S.
(1994)
J. Biol. Chem.
269,
30451-30456[Abstract/Free Full Text]
|
| 58.
|
Uemura, K.,
Sugiyama, E.,
and Taketomi, T.
(1991)
J. Biochem.
110,
96-102[Abstract/Free Full Text]
|
| 59.
|
Kozireski, D. K.,
Wu, G.,
and Ledeen, R. W.
(1999)
J. Neurosci. Res.
55,
107-118[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Ciesielski-Treska, J.,
Rebel, R. G.,
and Mandel, P.
(1977)
Differentiation
8,
31-37[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Riboni, L.,
Caminiti, A.,
Bassi, R.,
and Tettamanti, G.
(1995)
J. Neurochem.
64,
451-454[Medline]
[Order article via Infotrieve]
|
| 62.
|
Marchesini, S.,
Benaglia, G.,
Piccinotti, A.,
Bresciani, R.,
and Preti, A.
(1998)
FEBS Lett.
428,
115-117[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Palestini, P.,
Pitto, M.,
Ferraretto, A.,
Tettamanti, G.,
and Masserini, M.
(1998)
Biochemistry
37,
3143-3148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Tsuji, S.,
Yamashita, T.,
and Nagai, Y.
(1988)
J. Biochem.
104,
498-503[Abstract/Free Full Text]
|
| 65.
|
Hilbush, B. S.,
and Levine, J. M.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
5616-5620[Abstract/Free Full Text]
|
| 66.
|
Mahoney, J. A.,
and Schnaar, R.
(1997)
Biochim. Biophys. Acta
1328,
30-40[Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.